Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. (4th May 2018)

• Record Type: Journal Article
• Authors: Mariani, Sara; Bertero, Luca; Coppola, Vittoria; Saracco, Giorgio; Arezzo, Alberto; Francia Di Celle, Paola; Metovic, Jasna; Marchiò, Caterina; Cassoni, Paola
• Is Part Of: Expert review of molecular diagnostics. Volume 18:Number 5(2018)
• Page Start: 467
• Page End: 475
• Publication Date: 2018-05-04
• Subjects: UDG -- mutational artefacts -- PCR -- liquid biopsy -- sequencing -- FFPE; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2018.1468254
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Background : Technical biases due to PCR artefacts could represent an insidious obstacle for mutational analysis and precision medicine. Methods : The authors report a retrospective analysis by fast COLD-PCR and sequencing of 31 suboptimal tumor DNA samples obtained from FFPE tissues and liquid biopsies. Results : In FFPE tumor tissues and plasma liquid biopsies of patients with lung and colorectal adenocarcinoma, we observed a significant rate of artefactual KRAS mutations, unveiled by repeated analysis following UDG pretreatment as well as by simple repetition without UDG pretreatment step, thus suggesting a DNA damage different from cytosine deamination. UDG pretreatment was not only unnecessary to contrast artefacts occurrence, but also hampered the efficiency of mutational screening, reducing the analytical sensitivity. Taken individually or considered together, the reduced DNA input per reaction and UDG pretreatment limited the detection of 'real' mutated alleles, decreasing PCR sensitivity enough to hamper distinction between artefactual and true subclonal mutations of KRAS . Conclusions : Careful validation of analytical sensitivities should always be carried out through standard controls, and strategies other than UDG pretreatment need to be identified to avoid both amplification of artefactual mutations and failure to identify real subclonal mutations.